【摘要】 目的探讨α-L岩藻糖苷酶(AFU)作为肝癌标志物在肝脏炎症活动时的临床意义,以及远期随访AFU的变化情况,以确定AFU以诊断肝癌的价值。方法收集活动期慢性乙型肝炎患者血清42例,乙型肝炎肝硬化肝功异常患者血清48例,肝癌肝功异常患者血清42例,正常人血清40例,以放射免疫方法对AFU进行定量检测。结果乙型肝炎肝硬化患者AFU含量为(492.2±153)nmol(/mL·h),肝癌患者为(572.8±285)nmol(/mL·h),慢性肝炎患者为(452.62±176)nmol(/mL·h),三者均明显高于正常人血清(278.6±106nmol)(/mL·h)(P<0.05);肝癌患者AFU水平与肝硬化、慢性乙肝患者无显著差异(P>0.05)。肝硬化组、肝炎组中AFU升高患者随访3年后,肝硬化组发生肝癌几率较肝炎组高(P<0.05)。结论AFU在肝功异常的乙型肝炎肝硬化、慢性乙型肝炎和肝癌患者血清中均明显升高,但AFU的升高并非是肝癌的特异性指标。受肝脏炎症活动的影响,AFU作为肝癌标志物的诊断价值降低,但AFU对于远期评估肝癌的可能性具有较高的价值。更多还原

【Abstract】 Objective To explore α-L-fucosidase(AFU) diagnostic value as a marker of HCC in the patients with hepatitis. Methods Serum AFU was studied in 42 patients with HCC,42 patients with moderate to serious chronic hepatitis,48 patients with cirrhosis,and 40 controls with method of radioimmunoassay respectively. Results Serum AFU activity in HCC patients([572.8±285) nmol/(mL·h) ],liver cirrhosis patients([492.2±153) nmol/(mL·h) ],hepatitis patients([452.62±176) nmol/(mL·h) ]. There were significantly differentce from that of the healthy individuals. But there were not significant differences between HCC and other hepatic diseases. Conclusion Detection of serum AFU activity can not effectively differentiate patients with HCC from hepatitis and cirrhosis,and the diagnostic value of AFU as a serum marker of HCC is diminished.更多还原